Global Initiative on Takayasu Arteritis (GITA)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorMarmara University

About this trial

Takayasu's Arteritis Global Registry aims to bring a large group of patients from different parts of the world to analyse and compare the patients' demographic, clinical, laboratory, radiological and prognostic features with outcomes, approaches to diagnosis, assessment, management and therapeutic interventions in different centers. The present project provides for both a retrospective and a prospective longitudinal study. The study is designed as retrospective for patients already diagnosed with TAK and treated with available treatments. Also, the study is designed as prospective for patients diagnosed with TAK after the initiation of the Registry or the adhesion to the project. This is thought as a multicentre, international study addressed to all Centers that will want to contribute to the present project. The study is non-interventional: demographic, clinical and therapeutic data required over time are collected with the routine diagnostic, clinical and therapeutic procedures usually carried out for the optimal management of patients and according with good clinical practice.

Eligibility criteria

Qualifiers

Each patient must fullfill the ACR 1990 or ACR/EULAR 2021 criteria for Takayasu arteritis.

Patients (or legally acceptable representatives of subjects enrolled) have to

provide informed and free agreement to participate in the study and to disclose any medical event to the investigator. The parents or legally acceptable representative and the adolescent subject must be willing and able to comply with the study protocol requirements for the duration of the study

freely sign written and dated informed consent after being duly informed of the nature, significance, and implications of the study;

Disqualifiers

The patient does not full-fill the ACR 1990 or ACR/EULAR 2021 criteria for Takayasu arteritis

informed consent/assent is not provided and signed

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,000 Participants
are grouped into 1 trial group

Sponsors and collaborators